.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Global Perspective on Treatment of Hepatocellular Carcinoma

EP. 1: Diagnosis of HCC: Presentation of Disease

July 27th 2018

EP. 2: Global Multidisciplinary Care in HCC

July 27th 2018

EP. 3: Identifying Staging Systems for HCC

July 27th 2018

EP. 4: HCC: The Criteria for Adjuvant Therapy

July 27th 2018

EP. 5: Treating Hepatitis C in HCC

July 27th 2018

EP. 6: Neoadjuvant and Local Therapy in HCC

July 27th 2018

EP. 7: Rationale for TACE in Locally Advanced HCC

July 27th 2018

EP. 8: HCC Treatment: Sorafenib + TACE

July 27th 2018

EP. 9: Liver-Directed Therapy in HCC: Yttrium-90

July 27th 2018

EP. 10: Implication of Upfront Lenvatinib in HCC

July 27th 2018

EP. 11: HCC: Use of Lenvatinib and Sorafenib

July 27th 2018

EP. 12: Global Use of Regorafenib in HCC

July 27th 2018

EP. 13: Nivolumab and Checkpoint Inhibitors in HCC

July 27th 2018

EP. 14: Clinical Rationale for Cabozantinib in HCC

July 27th 2018

EP. 15: Emerging Agents for Treatment of HCC

July 27th 2018